RxDoctor Payments Data

Jeremy Crisp, MD

Family Medicine · Columbia, SCNPI 1205035342

Payments from drug & device makers

$5,146in general payments, 2019–2025

Across 296 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$680
  • Pfizer$596
  • AstraZeneca$456
  • Exact Sciences$367
  • Novo Nordisk$339
  • Dexcom, Inc.$320
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,146 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$211,053
Medicare patients
474
Services billed
8,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$94,326
MounjaroTirzepatide47$63,456
OzempicSemaglutide28$57,983
EliquisApixaban65$54,911
FarxigaDapagliflozin Propanediol22$32,036
TrulicityDulaglutide18$27,705
JanuviaSitagliptin Phosphate16$19,057
XareltoRivaroxaban14$10,171
MyrbetriqMirabegron14$9,799
Tresiba Flextouch U-200Insulin Degludec12$7,498
Rosuvastatin Calcium376$7,044
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$6,745
Celecoxib59$5,222
Breo ElliptaFluticasone/Vilanterol12$4,669
Atorvastatin Calcium349$3,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$188$94,32676 claims
Lilly USA, LLCMounjaro, Trulicity$680$91,16165 claims
Novo NordiskOzempic$339$57,98328 claims
PfizerEliquis$596$54,91165 claims
AstraZenecaFarxiga$456$32,03622 claims
MerckJanuvia$26$19,05716 claims
Johnson & JohnsonXarelto$70$10,17114 claims
Astellas Pharma US IncMyrbetriq$28$9,79914 claims
GSKBreo Ellipta$129$4,66912 claims
AbbVieSynthroid$256$3,39753 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →